1 Nerve growth factor (NGF), a powerful agent for the growth, dierentiation and regeneration of lesioned cells of the central and peripheral nervous systems, has in recent years been indicated as a potential therapeutic agent capable of reversing the processes of cell damage in neurodegenerative events in man. Since NGF does not cross the blood-brain barrier and central NGF administration requires invasive surgical procedures, the discovery of substances modulating in vivo NGF synthesis in the brain will be extremely useful for a possible clinical use of NGF. 2 The aim of the present study to analyse if the content of NGF in the brain of adult mice can be aected by peripheral administration of cholecystokinin-8 (CCK-8), a well known neuropeptide which has stimulant actions on neurons in the brain and promotes a variety of neurobehavioural eects both in man and rodents. 3 The dose-response and time course eects of an i.p. injection of CCK-8 on the NGF concentrations in the hippocampus, cortex, hypothalamus and pituitary of adult male mice were analysed by use of a sensitive immunoenzymatic assay for NGF. The eects of pretreatment with selective CCK A and CCK B receptor antagonists and atropine on the NGF response to CCK injection were also studied. 4 The eects of CCK-8 were dose-and time-dependent and the injection of 8 nmol kg 71 resulted in a 3 fold increase of NGF levels in the hypothalamus and pituitary, and about a 60% increase in the hippocampus. No eects were observed in the cortex. Pretreatment with a selective CCK A receptor antagonist blocked the CCK-induced NGF increase in the hypothalamus and pituitary. In the hippocampus the same eect was obtained with a CCK B receptor antagonist. Pretreatment with atropine suppressed the CCK-induced eects on NGF levels in all the brain regions examined. 5 Our results showing that i.p. injection with CCK-8 can modulate NGF levels in the brain through a mechanism which seems, in part, to be mediated via the vagal aerents, indicate that this neuropeptide may represent a useful pharmacological approach to enhance endogenous NGF levels in neuropathologies associated with a neurotrophin de®cit.
Introduction
Nerve growth factor (NGF), the ®rst and best characterized member of the neurotrophin family which includes BDNF and NT3-5 (Ebendal, 1992) , is known to play a major role in growth, dierentiation and maintenance of peripheral sensory and sympathetic neurones and neurones of the basal forebrain (Levi-Montalcini, 1987; Thoenen et al., 1987) . NGF prevents acute cholinergic cell damage in the medial septum and diagonal Broca's band following surgical lesion of the ®mbria-fornix in rodents (Hefti, 1986; Yunshao et al., 1991; Lapchak & Hefti, 1992) and monkeys (Koliatos et al., 1990) . Moreover, NGF is known to increase acetylcholine turnover (Kewitz et al., 1990) , neurite outgrowth (Levi-Montalcini, 1987) , neuronal survival and resistance to insults (Aloe, 1987; Shinego et al., 1991; Holtzman et al., 1996) and to protect neurones against hypoglycaemia and exocytotoxicity by stabilizing intracellular calcium (Cheng et al., 1993) . A decrease or lack of NGF or other neurotrophins has been proposed to induce several neuropathologies, including Alzheimer's disease (Eide et al., 1993; Scott & Crutcher, 1994) . Thus, NGF seems to have a number of potentially important clinical applications, some of which may bene®t patients with neurological brain diseases (Olson et al., 1992) . Based on these ®ndings, NGF has, in recent years, attracted considerable interest as a potential therapeutic agent capable of reversing the processes of cell damage in neurodegenerative events (Hefti & Shneider, 1989; Scott & Crutcher, 1994; Fricker, 1997) . A key limitation for the clinical use of NGF is that this protein does not cross the blood-brain barrier and invasive neurosurgical procedures, such as infusion into the ventricular space, or directly into brain parenchyma, are necessary for its delivery into the central nervous system (CNS; Harbaugh, 1989; Hefti & Shneider, 1989; Saran, 1992) . It is therefore conceivable that the identi®cation of molecules which can promote the synthesis of endogenous NGF in the brain would be extremely useful.
In recent years ®ndings from our and other laboratories have indicated that hormones, such as glucocorticoids (Aloe, 1989; Barbany & Persson, 1992; Lindholm et al., 1992) and testosterone (Katoh-Semba et al., 1994; Tirassa et al., 1997) can in¯uence basal levels of brain NGF. Although hormone therapy might be feasible in certain pathological conditions, it is known that hormones may present a number of undesirable side-eects in the brain (Sapolsky, 1992; Tirassa et al., 1997) .
The aim of the present in vivo study was to investigate the role played by cholecystokinin-8 (CCK-8) in the regulation of constitutive NGF content in the brain of adult mice. CCK-8 (Dockray, 1976; Beinfeld et al., 1981) and its receptors CCK A and CCK B (Hill et al., 1987; Wank et al., 1992) are largely distributed in the hippocampus, hypothalamus and cortex. In these brain regions CCK-8 acts as a neurotransmitter producing excitatory eects on neurones, which seem to be mediated by CCK receptors and blocked by selective CCK A and CCK B antagonists (Dodd & Kelly, 1981; Boden & Hill, 1988; Hicks et al., 1993) . Peripheral CCK-8 administration results in the stimulation of neuropeptide and hormone synthesis and/or release (Verbalis et al., 1986; Page et al., 1990; Kamilaris et al, 1992) , and promotes a variety of physiological and behavioural responses (Weatherford et al., 1992; Salorio et al., 1994) . Some of these CCK-8 eects are mediated by the activation of vagal aerent ®bres, since the response is abolished by selective CCK A antagonists and by vagotomy (McCann et al., 1988; Kamilaris et al., 1992; Wettstein et al., 1994) .
In this study we have analysed the dose-and timedependent eects of intraperitoneal (i.p.) CCK-8 administration on the NGF levels in the hippocampus, hypothalamus, cortex and pituitary, which represent the principal sites for NGF (Korshing et al., 1985; Spillantini et al., 1989) synthesis in brain. The eects of pretreatment with atropine, CCK A and CCK B receptor antagonists on the NGF response to i.p. injection with CCK-8 were also evaluated.
Methods

Subjects
Adult male CD1 mice (35 ± 40 g) were obtained from Charles River (Italy). They were housed 5 to a cage at constant room temperature (21+18C) with free access to water and standard food, and with a 12 h light-dark cycle. 71 CCK-8 or saline. The mice (n=6/group) were killed 15 min after the CCK injection. The brain tissues removed were stored at 7708C until used.
In these experiments a group of ®ve untreated mice (UT) was used as control of baseline NGF brain levels. Saline+sa-line treated mice (S+S) were considered as the internal control group in the experiments 3 and 4.
NGF measurement by enzyme immunoassay (ELISA)
The tissues were sonicated in extraction buer (0.1 M Tris-HCl pH 7.00; 400 mM NaCl, 0.1% Triton X100; 0.05% NaN 3 ; 2% BSA; 0.5% gelatine; 4 mM EDTA; 40 u ml 71 aprotinin; 0.2 mM PMSF; 0.2 mM benzetonium chloride; 2 mM benzamidine) followed by centrifugation at 15 000 r.p.m. for 30 min. The supernatants were used for the assay. The bioactive form of 2.5S NGF, puri®ed from mouse submaxillary glands and prepared in our laboratory according to the method of Bocchini and Angeletti, was used as standard. NGF was dissolved in extraction buer and the standard curve was in a range of 0.015 pg ml 71 and 1 ng ml 71 . ELISA was performed as described by Weskamp and Otten (1987) . Speci®c NGF binding was assessed by use of a moncolonal mouse anti b-2.5S NGF (Boehringer Mannheim) which reacts with both the 2.5S and 7S NGF biologically active forms. Absorbance of samples and standards was corrected for non-speci®c binding (i.e. the absorbance in a well coated with puri®ed mouse IgG). The NGF content in the samples was determined in relation to NGF standard curve. Data were not corrected for recovery of NGF from samples, which was routinely 70 ± 90%, and was accepted only when the values were 42 s.d. above the blank. With these criteria, the limit of sensitivity of NGF ELISA averaged at 0.5 pg per assay. Moreover, the speci®city of NGF measurement by ELISA was assessed by use of recombinant and biologically active NGF as described previously (Weskamp & Otten, 1987; Bracci-Laudiero et al., 1992) . The NGF data are presented as mean+s.d. The Kruskal-Wallis nonparametric analysis of variation with multiple comparisons were used for signi®cance testing. P values less than 0.05 were considered signi®cant.
NGF characterization by high-performance liquid chromatography (h.p.l.c.)
The entire brain (excluding the cerebellum) of untreated mice and saline-or CCK-8 (8 nmol kg 71 )-treated mice (n=3/group) was homogenized by sonication in 20 mM Tris, 40 mM NaCl (pH 7.2) and centrifuged. The supernatants were dialyzed against 5 mM Tris, 10 mM NaCl pH 7.2 for 16 h at 48C followed by a second over-night dialysis against 50 mM sodium acetate, 10 mM NaCl pH 5.0. Before the samples were lyophilized, the supernatants were dialyzed against 5 mM sodium acetate, pH 5.0, and re-centrifuged to obtain clean samples. The lyophilized brain samples were re-dissolved in 500 ml of 10 mM sodium acetate, 100 mM NaCl, pH 5.0, before being applied to the h.p.l.c. analysis.
A progel TSK (3000PW-dp 10 mm, 7.5 mm i.d.630 cm) column equipped with a TSK guard column was used. The column was eluted (0.5 ml min 71 ) with 10 mM sodium acetate, 100 mM NaCl (pH 5.0) for 60 min at room temperature. Fractions of 1 ml were collected and utilized to assess the presence of NGF by ELISA. The h.p.l.c. column was calibrated with 40 mg of puri®ed and bioactive murine 2.5 S NGF extracted from submaxillary glands. The above standard was also added to the brain samples from the untreated mice. To avoid possible contamination of the h.p.l.c. column, the samples from the saline and CCK-8-treated mice were analysed ®rst.
Drugs
The following drugs were used: cholecsytokinin-8 (CCK 26-33) was obtained from Peninsula Lab (U.S.A.); CCK B receptor antagonist: PD 135-158 (N-methyl-D-glucamine salt) and CCK A receptor antagonist: CR1409 (lorglumide sodium salt (C 22 H 31 Cl 2 N 2 O 4 Na) were obtained from Research Biochemical International (U.S.A.); atropine sulphate salt (Sigma Chemicals Italy). All drugs were administered intraperitoneally (i.p.).
Results
Intraperitoneal injection with CCK-8 increased NGF levels in the hippocampus, hypothalamus and pituitary, while in the cortex no signi®cant changes were observed. Table 1 shows the dose-response eects of i.p. CCK injection on brain NGF levels (Experiment 1). The highest NGF increase was observed at the dose of 8 nmol kg 71 which caused an NGF increase of about 3 fold in hypothalamus and pituitary and about 60% in the hippocampus (P50.01). Compared to saline-treated mice, the CCK doses of 4 and 16 nmol kg 71 were also able to upregulate the basal NGF levels in hippocampus, hypothalamus and pituitary, but no changes were seen in the cortex. The dose of 8 nmol kg 71 was used to characterize the CCKinduced NGF release in the brain by h.p. The time-course study (Experiment 2) showed that CCK-8 induced a signi®cant increase in NGF levels in the hippocampus 15 and 30 min after the injection and NGF levels returned to basal levels at 60 min (see Figure 3a) , whereas in the hypothalamus, although the NGF levels of CCK-treated mice remained higher than those of untreated ones at all time points examined (P50.01 vs untreated mice), they were statistically dierent from the saline treated ones only at 15 min (see Figure 3b) . In the pituitary, where the NGF levels of saline-treated mice increased during the time of observation (15 min=1322+160; 30 min=4451+1000*; 60 min=7694+1751* NGF pg g 71 tissue; *P50.01 vs UT), the NGF content of the CCK-treated mice was signi®cantly increased compared with both control and saline-treated mice. The time course study showed that in CCK-treated mice the pituitary NGF levels were about 3 fold higher than in the saline-treated ones at all the time points examined (15 min=4626+430; 30 min=14 000+2855; 60 min=26.000 +1815 NGF pg g 71 tissue; P50.0001 vs saline NGF values at corresponding time). In the cortex, although a small increase in NGF levels was observed 30 and 60 min after the CCK-8 injection, it was signi®cant when compared with saline-treated mice (data not shown).
The results of the eects of pretreatment with CCK receptor antagonists (Experiment 3) on the NGF response to CCK injection, are shown in Figures 4a and b . Pretreatment with the CCK B receptor antagonist (PD 135-158) blocked the CCKinduced NGF level increase in the hippocampus, while pretreatment with the CCK A receptor antagonist (CR1409) did not (see Figure 4a) . Opposite eects were found in the hypothalamus (Figure 4b) , where the NGF response to CCK injection was suppressed by pretreatment with CCK A receptor antagonist but not by the CCK B receptor antagonist.
Compared to the internal control group (saline+saline) no signi®cant eects of treatment with either of the CCK receptor antagonists alone on NGF levels in brain were noted (see Figure 4a and b) .
In mice pretreated with atropine, the ability of CCK-8 to increase the brain NGF levels after i.p. injection was abolished in both the regions examined ( Figure 5 ). No changes in NGF levels were noted in the brain of mice treated with atropine+saline when compared to the saline+saline treated mice ( Figure 5 ).
Conclusion
In the present study we demonstrated that i.p. injection with CCK-8 induced a signi®cant increase of NGF in adult mouse hippocampus, hypothalamus and pituitary. No changes of NGF levels were observed in the cortex. However, it is possible that cortical NGF levels may be aected at dierent times and/ or doses of CCK, which have not been considered in the present study. CCK-8 does not cross the blood-brain barrier and is rapidly processed to smaller biologically active and inactive fragments (Davis & Konings, 1993 ). Thus it may be possible that the form of CCK-8 used in this study, was not active long enough to produce prolonged and/or extensive eects in brain. Although these latter aspects require further investigation, the present ®ndings indicate that CCK aects NGF production in two of the major NGF-synthesizing brain regions: the hippocampus (Korshing et al., 1985) and hypothalamus (Spillantini et al., 1989) . In these regions, as well as in the pituitary, the eects of CCK were observed in a dose range of 4 ± 16 nmol kg other neuropeptides and hormones in the brain (Verbalis et al., 1986; Page et al., 1990; Kamilaris et al., 1992) , to induce immediate early gene expression (Day et al., 1994) and to in¯uence centrally-mediated behavioural eects (Bloch et al., 1987; Weatherford et al., 1992; Salorio et al., 1994) . Thus, our ®ndings showing that CCK alters brain NGF levels, extended these observations and con®rm that peripheral CCK-8 administration can have eects on the brain. The h.p.l.c. analysis of the brain samples from saline-and CCK-8-treated mice con®rms that the CCK-8-induced NGF increase in the brain is predominantly due to an increase of the biologically active form of NGF. The results of the h.p.l.c. analysis are consistent with results obtained by NGF-ELISA and, in agreement with previous data (Weskamp & Otten, 1987; Bracci-Laudiero et al., 1992) showing that the ELISA is speci®c for the bioactive 2.5S NGF form and does not seem to detect the proteins which may contaminate the NGF preparation, and/or NGF forms dierent from 2.5S or 7S NGF. However, in our experimental conditions, we cannot exclude the possibility that CCK-8 acts through a mechanism which increases the processing of NGF precursor and/or the NGF utilization by brain cells.
We also observed that the NGF response to CCK administration was abolished following pretreatment with the selective CCK A and CCK B receptor antagonists and atropine. While CCK A and CCK B receptor antagonists have opposite eects in the hypothalamus and hippocampus, pretreatment with atropine blocks the NGF response to CCK in both brain regions. Further studies are needed to understand the role of the two CCK receptors in mediating the eects on NGF levels in the brain. Nevertheless, it is interesting to note that CCK A and CCK B receptor antagonists given alone have no eect on the NGF brain levels. CCK does not readily cross the bloodbrain barrier (Oldendorf, 1981) , which indicates that the NGF increase in brain following CCK-8 i.p. injection is mediated by the activation of both the CCK receptors localized outside the blood-brain barrier. Moreover, in agreement with previous observations (McCann et al., 1988; Kamilaris et al., 1992; Wettstein et al., 1994) , the ®nding that atropine can block the CCK eect supports the hypothesis that the central eects of peripheral CCK administration are at least in part mediated by vagal aerent activity. This hypothesis may also be supported by the fact that CCK, when peripherally injected, can have access to speci®c receptors located at some speci®c brain sites where the bloodbrain barrier is incomplete, i.e. the nucleus tractus solitarius (NTS; Harro et al., 1993) . In this nucleus, which receives a large number of vagal aerents and sends a very dense network of ®bre to dierent superior brain regions, CCK A and CCK B receptors have been localized (Corp et al., 1993) . Transection of vagal aerents entering in the hindbrain results in substantial loss of CCK binding density in NTS, indicating that CCK receptors in this nucleus are associated with terminals of vagal origin (Moran et al., 1990) . Furthermore, it has been observed that neither CCK A nor CCK B antagonists alone speci®cally inhibited CCK binding in the vagus, while combined treatment with the two antagonists saturated the vagal CCK binding sites (Mercer & Lawrence, 1992; Corp et al., 1993) . Although a functionally signi®cant role for vagal CCK A receptors has been suggested by behavioural and electrophysiological studies (for a review see Moran & Schwartz, 1994) , a role for the vagal CCK B receptors remains to be determined. Nevertheless, it may be possible that the NGF increase in brain following CCK-8 i.p. injections is associated with dierent physiological eects of this peptide which are mediated by the two classes of vagal receptors.
Alternatively, the converse eects of the CCK A and CCK B receptor antagonists may be related to the interaction of the dierent receptor subtypes with dierent CCK fragments derived from the processing of the unstabilized form of CCK-8 administered. CCK-8 is rapidly metabolized and converted into bioactive and inactive fragments, including CCK-4 which is known to bind with high anity to CCK B but not CCK A . Similarly to CCK-8, CCK-4 produces eects in brain (Moran & Schwartz, 1994) , thus it is possible that regional eects of the antagonist pre-treatment re¯ect the action of these two peptides and the shift from CCK A to CCK B sensitivity by a mechanism similar to that suggested for the longitudinal muscle (Davis & Konings, 1993) .
Although further studies will be necessary to elucidate the mechanism by which CCK-8 and its receptors modulate the central release of bioactive proteins and peptides, our ®ndings, that amounts of CCK very close to the physiological circulating levels (Linden et al., 1989 ) enhance brain NGF levels through a peripheral injection can be helpful to understand better the regulation of NGF production in brain, as well as that of the other neurotrophins.
Moreover, since a therapeutic role has been proposed for exogenous NGF administration (Hefti & Shneider, 1989; Scott & Crutcher, 1994; Fricker, 1997) but its clinical utilization is currently limited by the fact that signi®cant amounts of NGF do not cross the blood-brain barrier and that cerebral NGF treatment is too invasive (Harbaugh, 1989; Hefti & Shneider, 1989; Saran, 1992) , the possibility that peripheral treatment with CCK enhances NGF in brain may provide a pharmacological tool in some neuropathologies characterized by a de®cit of neutrophins.
